RDY
Dr. Reddy's Laboratories Ltd.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · IN
$14.53
−1.62%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$14.76
From 52W high−5.53%
Volume4.17M
Market cap$12.11B
P/E (TTM)40.3x
P/S (TTM)3.4x
Div yield1.02%
Key dataNov 5, 2026
Open
$14.76
From 52W high
−5.53%
Volume
4.17M
Market cap
$12.11B
ValuationView details →
P/E (Fwd)
26.2x
EV/EBITDA
21.1x
P/E (TTM)
40.3x
RSI (14)
77.5
MomentumView details →
1D Return
−1.62%
YTD Return
+4.20%
SummaryUpdated Sep 1, 2026
Dr. Reddy's Laboratories Limited (NYSE:RDY) is an Indian multinational pharmaceutical company founded in 1984 and headquartered in Hyderabad, India. The company has evolved from a small startup into one of India's largest pharmaceutical companies, going public on the New York Stock Exchange in 2001. Dr. Reddy's operates as an integrated pharmaceutical company with a global presence, manufacturing and marketing generic drugs, active pharmaceutical ingredients, and developing proprietary products across multiple therapeutic areas including cardiovascular, gastrointestinal, oncology, and diabetes treatments.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration approved a generic injectable version of lenacapavir for HIV prevention on November 2, 2026.2d agoThe U.S. Food and Drug Administration granted DR REDDYS LABORATORIES LTD tentative approval to make a generic version of an HIV-prevention medicine.2d agoThe DR REDDYS LABORATORIES LTD accepted uniQure N.V.'s Biologics License Application for investigational Huntington's disease gene therapy ifezuntirgene inilparvovec under the Accelerated Approval pathway.3d ago